Last week, HIV drug developer Koronis Pharmaceuticals Inc. said it was exploring a range of financing options, including a possible listing on London's AIM exchange, to access adequate funding for mid- and late-stage activities. But one alternative the Seattle-based firm won't be considering is a traditional initial public offering (IPO) on Nasdaq. Read More
